Experts agree that the urological cancer patient will benefit greatly if the delivered treatment is the result of a combined effort. Collaboration of experts from various fields is, therefore, necessary to take cancer-related research and medical practice to the next level. [More]

U.S. Health and Human Services Secretary Kathleen Sebelius is to be commended for publicly stating the government panel opposing mammograms is "an outside independent panel of doctors and scientists who ... do not set federal policy and ... don't determine what services are covered by the federal government." [More]

Astellas Pharma Inc. and XenoPort, Inc. today announced that a new drug application (NDA) has been filed with the Pharmaceuticals and Medical Device Agency (PMDA) in Japan for ASP8825 (gabapentin enacarbil), also known as XP13512, as a potential treatment for restless legs syndrome (RLS). [More]

Just as fly paper captures insects, an innovative new device with nano-sized features developed by researchers at UCLA is able to grab cancer cells in the blood that have broken off from a tumor. [More]

Dong-A Pharmaceutical Co., Ltd. and Dong-A PharmTech, Co. Ltd. announced today that it has completed a 240 patient once-a-day dosing clinical study of udenafil, its new long acting phosphodiesterase type 5 (PDE-5) inhibitor for erectile dysfunction (ED). [More]

VIVUS, Inc. today announced positive results from REVIVE (TA-301), a phase 3 pivotal study evaluating the safety and efficacy of avanafil, an investigational drug candidate for the treatment of erectile dysfunction (ED), in 646 patients. [More]

International prostate cancer expert Dr. Oliver Sartor of Tulane Cancer Center is the first oncologist in the United States to offer patients an experimental new treatment for late-stage prostate cancer through a multi-center clinical trial that is currently recruiting patients at 100 sites across 20 countries worldwide. [More]

Uroplasty, Inc. (AMEX: UPI), a medical device company developing, manufacturing and marketing innovative proprietary products for the treatment of voiding dysfunctions, today announced that nine abstracts outlining study results submitted by various researchers have been accepted for presentation at the 2010 Annual Meeting of the Society for Urodynamics and Female Urology (SUFU), February 23-27, 2010 in St. Petersburg, FL. Presentations accepted were for both Uroplasty's Urgent® PC Neuromodulation System and Macroplastique® urethral bulking agent products. [More]

Frank Browning reports for Kaiser Health News on how the health reform debate is playing out in rural Kentucky. "From a strip-mined bluff at the edge of this famous mountain town you can see one of the most concentrated and diverse sets of medical facilities in rural America: a general hospital, a psychiatric hospital, a university-based rural health care center and clinics for primary care, cancer, urology, cardiology, addiction and ear-nose-and throat problems. [More]

Warner Chilcott plc today announced a 20,000,000 share secondary offering of its ordinary shares by certain selling shareholders. The selling shareholders include funds affiliated with Bain Capital Partners, DLJ Merchant Banking, J.P. Morgan Partners (advised by CCMP Capital) and Thomas H. Lee Partners, L.P., certain other institutional investors and members of the Company's senior management. The offering is being conducted as a public offering pursuant to an effective shelf registration statement under the Securities Act of 1933. The Company will not receive any proceeds from the sale of the shares but will pay the expenses of the offering. [More]

On this Friday the 13th, the headlines offer an array of health policy views -- from the possibility of including a Medicare payroll tax in health reform legislation to continuing analysis of the overhaul's winners and losers as well as the CDC's new estimate of the far-reach of the swine flu. [More]

Medtronic, Inc. today announced the kick-off of an educational campaign aimed at raising awareness among women of overactive bladder (OAB), a serious condition that can severely impact patients’ lives. This new campaign, conducted in partnership with leading patient advocacy groups focused on women’s health will help to raise awareness of the prevalence of bladder control problems and encourage patients to find effective treatment options – including and beyond medications. [More]

Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, announced today the acquisition of Duraclon® (clonidine hydrochloride injection) and Methadone Hydrochloride Injection USP from Xanodyne Pharmaceuticals, Inc. [More]

Endo Pharmaceuticals announced today that it has reached a settlement with LecTec Corporation on outstanding patent litigation related to LecTec's U.S. Patent Nos. 5,536,263 and 5,741,510. [More]

In a recent New York Times article, the American Cancer Society (ACS) ignited a major controversy over the benefits of cancer screening, specifically with regards to their breast and prostate cancer guidelines. In the article, Dr. Otis Brawley, chief medical officer of the ACS, responded to a study in the current issue of the Journal of the American Medical Association. [More]